FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3026263867> ?p ?o ?g. }

• W3026263867 endingPage "678" @default.
• W3026263867 startingPage "669" @default.
• W3026263867 abstract "Rationale & Objective Glomerular C4d (C4dG) as an indicator of the lectin pathway of complement activation in immunoglobulin A nephropathy (IgAN) has been associated with more severe kidney damage. Recent studies have suggested that vascular lesions in IgAN biopsy specimens with complement deposition are also associated with disease progression. We aimed to study the clinical significance of arteriolar C4d (C4dA) in IgAN kidney biopsy tissue. Study Design Retrospective cohort study. Setting & Participants Kidney biopsy specimens from 126 adults with IgAN diagnosed by Oxford classification criteria were stained using immunohistochemistry and classified according to C4dG and C4dA deposition. Additionally, vascular lesions including acute and chronic microangiopathy, arteriolar hyalinosis, and arterial intima fibrosis were characterized. Predictor C4dA. Outcome Progressive kidney disease, defined as a decline in estimated glomerular filtration rate by ≥50% or occurrence of kidney failure. Analytical Approach The association of C4dA and C4dG with baseline clinical and histologic characteristics, as well as progressive kidney disease, were assessed with survival analysis using multivariable Cox regression analysis. Results C4dA was identified in 21 (17%) patients and was associated with mean arterial pressure, arterial intima fibrosis, and chronic microangiopathy. C4dA was also significantly associated with C4dG and both were associated with progressive kidney disease. In regression analysis, C4dA remained significantly associated with progressive kidney disease after adjusting for other significant predictors, including baseline estimated glomerular filtration rate, mean arterial pressure, and the presence of crescents. Limitations Findings based on the retrospective evaluation of a single center’s experience, limited number of events, a small number of patients with a broad range of kidney disease stages, and use of immunohistochemistry rather than immunofluorescence to detect C4d. Conclusions C4dA is a potential biomarker for disease progression in IgAN. It should be further investigated in larger cohorts to determine the value of C4dA in improving prediction of IgAN disease progression. Glomerular C4d (C4dG) as an indicator of the lectin pathway of complement activation in immunoglobulin A nephropathy (IgAN) has been associated with more severe kidney damage. Recent studies have suggested that vascular lesions in IgAN biopsy specimens with complement deposition are also associated with disease progression. We aimed to study the clinical significance of arteriolar C4d (C4dA) in IgAN kidney biopsy tissue. Retrospective cohort study. Kidney biopsy specimens from 126 adults with IgAN diagnosed by Oxford classification criteria were stained using immunohistochemistry and classified according to C4dG and C4dA deposition. Additionally, vascular lesions including acute and chronic microangiopathy, arteriolar hyalinosis, and arterial intima fibrosis were characterized. C4dA. Progressive kidney disease, defined as a decline in estimated glomerular filtration rate by ≥50% or occurrence of kidney failure. The association of C4dA and C4dG with baseline clinical and histologic characteristics, as well as progressive kidney disease, were assessed with survival analysis using multivariable Cox regression analysis. C4dA was identified in 21 (17%) patients and was associated with mean arterial pressure, arterial intima fibrosis, and chronic microangiopathy. C4dA was also significantly associated with C4dG and both were associated with progressive kidney disease. In regression analysis, C4dA remained significantly associated with progressive kidney disease after adjusting for other significant predictors, including baseline estimated glomerular filtration rate, mean arterial pressure, and the presence of crescents. Findings based on the retrospective evaluation of a single center’s experience, limited number of events, a small number of patients with a broad range of kidney disease stages, and use of immunohistochemistry rather than immunofluorescence to detect C4d. C4dA is a potential biomarker for disease progression in IgAN. It should be further investigated in larger cohorts to determine the value of C4dA in improving prediction of IgAN disease progression." @default.
• W3026263867 created "2020-05-29" @default.
• W3026263867 creator A5008668138 @default.
• W3026263867 creator A5017132626 @default.
• W3026263867 creator A5020683293 @default.
• W3026263867 creator A5025299489 @default.
• W3026263867 creator A5034520349 @default.
• W3026263867 creator A5034940975 @default.
• W3026263867 creator A5037284641 @default.
• W3026263867 creator A5046122152 @default.
• W3026263867 creator A5060480065 @default.
• W3026263867 creator A5064364837 @default.
• W3026263867 creator A5078607536 @default.
• W3026263867 date "2020-11-01" @default.
• W3026263867 modified "2023-10-01" @default.
• W3026263867 title "Arteriolar C4d in IgA Nephropathy: A Cohort Study" @default.
• W3026263867 cites W1974743039 @default.
• W3026263867 cites W2011498897 @default.
• W3026263867 cites W2044823767 @default.
• W3026263867 cites W2048959030 @default.
• W3026263867 cites W2072019856 @default.
• W3026263867 cites W2086570276 @default.
• W3026263867 cites W2110433136 @default.
• W3026263867 cites W2113470371 @default.
• W3026263867 cites W2120330318 @default.
• W3026263867 cites W2129925362 @default.
• W3026263867 cites W2132000640 @default.
• W3026263867 cites W2135654016 @default.
• W3026263867 cites W2136537784 @default.
• W3026263867 cites W2141275524 @default.
• W3026263867 cites W2142932947 @default.
• W3026263867 cites W2149407433 @default.
• W3026263867 cites W2151689843 @default.
• W3026263867 cites W2152853007 @default.
• W3026263867 cites W2155965977 @default.
• W3026263867 cites W2166885924 @default.
• W3026263867 cites W2169743937 @default.
• W3026263867 cites W2186629139 @default.
• W3026263867 cites W2219142524 @default.
• W3026263867 cites W2408326472 @default.
• W3026263867 cites W2588568602 @default.
• W3026263867 cites W2602196428 @default.
• W3026263867 cites W2610345163 @default.
• W3026263867 cites W2613961195 @default.
• W3026263867 cites W2626284838 @default.
• W3026263867 cites W2768410307 @default.
• W3026263867 cites W2799619597 @default.
• W3026263867 cites W2801016999 @default.
• W3026263867 cites W2910019464 @default.
• W3026263867 cites W2911011964 @default.
• W3026263867 cites W2915072558 @default.
• W3026263867 cites W2924864047 @default.
• W3026263867 cites W2929806984 @default.
• W3026263867 cites W2937346600 @default.
• W3026263867 cites W2945741224 @default.
• W3026263867 cites W2970501086 @default.
• W3026263867 cites W2971813790 @default.
• W3026263867 cites W4247172809 @default.
• W3026263867 doi "https://doi.org/10.1053/j.ajkd.2020.03.017" @default.
• W3026263867 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32439421" @default.
• W3026263867 hasPublicationYear "2020" @default.
• W3026263867 type Work @default.
• W3026263867 sameAs 3026263867 @default.
• W3026263867 citedByCount "17" @default.
• W3026263867 countsByYear W30262638672020 @default.
• W3026263867 countsByYear W30262638672021 @default.
• W3026263867 countsByYear W30262638672022 @default.
• W3026263867 countsByYear W30262638672023 @default.
• W3026263867 crossrefType "journal-article" @default.
• W3026263867 hasAuthorship W3026263867A5008668138 @default.
• W3026263867 hasAuthorship W3026263867A5017132626 @default.
• W3026263867 hasAuthorship W3026263867A5020683293 @default.
• W3026263867 hasAuthorship W3026263867A5025299489 @default.
• W3026263867 hasAuthorship W3026263867A5034520349 @default.
• W3026263867 hasAuthorship W3026263867A5034940975 @default.
• W3026263867 hasAuthorship W3026263867A5037284641 @default.
• W3026263867 hasAuthorship W3026263867A5046122152 @default.
• W3026263867 hasAuthorship W3026263867A5060480065 @default.
• W3026263867 hasAuthorship W3026263867A5064364837 @default.
• W3026263867 hasAuthorship W3026263867A5078607536 @default.
• W3026263867 hasBestOaLocation W30262638672 @default.
• W3026263867 hasConcept C126322002 @default.
• W3026263867 hasConcept C134018914 @default.
• W3026263867 hasConcept C142724271 @default.
• W3026263867 hasConcept C159641895 @default.
• W3026263867 hasConcept C167135981 @default.
• W3026263867 hasConcept C2777878052 @default.
• W3026263867 hasConcept C2778653478 @default.
• W3026263867 hasConcept C2779134260 @default.
• W3026263867 hasConcept C2780091579 @default.
• W3026263867 hasConcept C2781184683 @default.
• W3026263867 hasConcept C555293320 @default.
• W3026263867 hasConcept C71924100 @default.
• W3026263867 hasConcept C90924648 @default.
• W3026263867 hasConceptScore W3026263867C126322002 @default.
• W3026263867 hasConceptScore W3026263867C134018914 @default.
• W3026263867 hasConceptScore W3026263867C142724271 @default.
• W3026263867 hasConceptScore W3026263867C159641895 @default.

• next